Remove 2018 Remove EBITDA Remove Marketability Remove Specific Risk
article thumbnail

PARAMETERS UPDATE P5.8

Equidam

You can refer to the table at this link to see how they will change for your country specifically. Industry EBITDA multiples used in the VC and DCF with multiple methods Our multiples are based on public market conditions at the beginning of the current year. Data is taken at the global level and aggregated by industry.

EBITDA 44
article thumbnail

MAEjor Ruling: Delaware Court of Chancery Finds Target Suffers Material Adverse Effect and Acquirer Could Back Out of Transaction

Cooley M&A

2018-0300-JTL (Del. In April 2017, Fresenius agreed to acquire Akorn, a US-based, Nasdaq-listed specialty manufacturer and marketer of generic prescription and over-the-counter pharmaceutical products, for $35 per share or approximately $4.75 Therefore, the board should have a high degree of confidence in deal certainty.